Tag: Lusvertikimab
OSE Immunotherapeutics announces the end of recruitment in the Phase 2 clinical study of Lusvertikimab evaluated in patients suffering from ulcerative colitis – 03/18/2024 at 07:30
Nantes, France – March 18, 2024, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the end of recruitment in the Phase 2b clinical trial evaluating the…
OSE Immunotherapeutics pursues clinical development in ulcerative colitis with full worldwide rights to Lusvertikimab – 05/12/2023 at 18:00
• Lusvertikimab (OSE-127), a ‘first-in-class’ product, is the most clinically advanced anti-IL-7R monoclonal antibody. • Ongoing phase 2 trial in ulcerative colitis (sponsor OSE Immunotherapeutics) after a positive futility analysis…
OSE Immunotherapeutics alone continues its clinical study on Lusvertikimab – 05/12/2023 at 18:11
(AOF) – OSE Immunotherapeutics announces that it is continuing its phase 2 clinical study of Lusvertikimab having obtained full worldwide rights to the product. OSE and Servier signed a two-step…